Lucid Diagnostics IncNASDAQ:LUCD
- LAST PRICE0.7965
- TODAY'S CHANGE (%)-0.0025 (-0.3129%)
- Bid / Lots0.7651/ 12
- Ask / Lots0.8000/ 3
- Open / Previous Close0.7950 / 0.7990
- Day Range
- 52 Week Range
- Volume118,257
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LUCD |
|---|---|---|
| 09:32 ET | 3536 | 0.7875 |
| 09:34 ET | 12021 | 0.7654 |
| 09:38 ET | 311 | 0.7651 |
| 09:41 ET | 600 | 0.7899 |
| 09:43 ET | 429 | 0.7899 |
| 09:50 ET | 9000 | 0.785 |
| 09:56 ET | 3083 | 0.77041 |
| 09:57 ET | 2625 | 0.78 |
| 10:06 ET | 200 | 0.7751 |
| 10:08 ET | 900 | 0.7775 |
| 10:10 ET | 2100 | 0.78 |
| 10:12 ET | 201 | 0.7775 |
| 10:21 ET | 192 | 0.78 |
| 10:26 ET | 1000 | 0.77894 |
| 10:39 ET | 250 | 0.775 |
| 10:42 ET | 1500 | 0.7798 |
| 10:44 ET | 927 | 0.775 |
| 10:48 ET | 1048 | 0.7774 |
| 10:51 ET | 100 | 0.7799 |
| 10:53 ET | 345 | 0.7799 |
| 10:57 ET | 2700 | 0.77745 |
| 11:00 ET | 5600 | 0.7799 |
| 11:04 ET | 2037 | 0.7775 |
| 11:06 ET | 720 | 0.778 |
| 11:08 ET | 14695 | 0.79 |
| 11:09 ET | 6289 | 0.7905 |
| 11:20 ET | 1120 | 0.7999 |
| 11:26 ET | 100 | 0.7955 |
| 11:27 ET | 11100 | 0.7999 |
| 11:29 ET | 4464 | 0.7907 |
| 11:47 ET | 300 | 0.7874 |
| 12:03 ET | 100 | 0.7912 |
| 12:30 ET | 1364 | 0.79045 |
| 01:14 ET | 100 | 0.79 |
| 01:21 ET | 281 | 0.781 |
| 01:32 ET | 730 | 0.781091 |
| 01:39 ET | 111 | 0.7999 |
| 01:46 ET | 1250 | 0.79595 |
| 02:02 ET | 1000 | 0.7999 |
| 02:09 ET | 100 | 0.7802 |
| 02:11 ET | 200 | 0.798999 |
| 02:29 ET | 1996 | 0.78 |
| 02:31 ET | 200 | 0.799 |
| 02:38 ET | 500 | 0.795929 |
| 02:42 ET | 375 | 0.780901 |
| 02:51 ET | 237 | 0.7904 |
| 02:56 ET | 100 | 0.8 |
| 03:03 ET | 200 | 0.799899 |
| 03:05 ET | 200 | 0.7999 |
| 03:25 ET | 103 | 0.8 |
| 03:32 ET | 2820 | 0.7811 |
| 03:34 ET | 5560 | 0.789 |
| 03:52 ET | 100 | 0.7882 |
| 03:56 ET | 100 | 0.7904 |
| 03:57 ET | 1856 | 0.7882 |
| 03:59 ET | 1727 | 0.7965 |
Apr 12, 2024
DJ Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham, from 4:47AM ET on Friday Apr 12, 2024 by Dow Jones
4:47AM ET on Friday Apr 12, 2024 by Dow Jones
Apr 8, 2024
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference, from 8:30AM ET on Monday Apr 08, 2024 by Dow Jones
8:30AM ET on Monday Apr 08, 2024 by Dow Jones
Mar 27, 2024
DJ Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald, from 10:13AM ET on Wednesday Mar 27, 2024 by Dow Jones
10:13AM ET on Wednesday Mar 27, 2024 by Dow JonesDJ Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham, from 5:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
5:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
Mar 26, 2024
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results, from 7:32PM ET on Tuesday Mar 26, 2024 by Dow Jones
7:32PM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lucid Diagnostics Inc | 38.5M | -0.6x | --- |
SeaStar Medical Holding Corp | 40.7M | -0.2x | --- |
BioRegenx Inc | 35.0M | -17.9x | --- |
bioAffinity Technologies Inc | 32.1M | -3.1x | --- |
Nutriband Inc | 31.6M | -5.8x | --- |
Femasys Inc | 29.0M | -1.4x | --- |
Company Information
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.
Contact Information
- Headquarters
- 360 Madison Avenue, 25Th FloorNEW YORK, NY, United States 10017
- Phone
- 212-949-4319
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Lishan Aklog
- President, Chief Operating Officer
- Shaun O'Neil
- Vice Chairman of the Board
- Stanley Lapidus
- Chief Financial Officer, Company Secretary
- Dennis Mcgrath
- General Counsel, Secretary
- Michael Gordon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $38.5M |
|---|---|
Revenue (TTM) | $2.4M |
Shares Outstanding | 48.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.26 |
Book Value | $-0.05 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 15.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,997.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
